VION Biosciences

Iron Path Capital's life-sciences roll-up platform providing manufacturing, specialty reagents and services to biopharma; acquired Prolytix (2026) and Aldon Corporation (2023). Distinct from Vincere Biosciences and Lo Biosciences.